Kiniksa Pharmaceuticals International (NASDAQ:KNSA) & Revolution Medicines (NASDAQ:RVMD) Critical Contrast

Revolution Medicines (NASDAQ:RVMD) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

Profitability

This table compares Revolution Medicines and Kiniksa Pharmaceuticals International’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-88.20%	-57.85%
Kiniksa Pharmaceuticals International	9.59%	13.65%	10.09%

Volatility & Risk

Revolution Medicines has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.05, suggesting that its share price is 95% less volatile than the S&P 500.

Institutional & Insider Ownership

94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 53.9% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. 7.6% of Revolution Medicines shares are owned by insiders. Comparatively, 52.0% of Kiniksa Pharmaceuticals International shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current recommendations for Revolution Medicines and Kiniksa Pharmaceuticals International, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1	1	19	1	2.91
Kiniksa Pharmaceuticals International	0	2	8	0	2.80

Revolution Medicines currently has a consensus target price of $161.79, suggesting a potential downside of 20.58%. Kiniksa Pharmaceuticals International has a consensus target price of $87.38, suggesting a potential upside of 13.84%. Given Kiniksa Pharmaceuticals International’s higher possible upside, analysts clearly believe Kiniksa Pharmaceuticals International is more favorable than Revolution Medicines.

Valuation & Earnings

This table compares Revolution Medicines and Kiniksa Pharmaceuticals International”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58 million	3,770.57	-$1.13 billion	($8.82)	-23.10
Kiniksa Pharmaceuticals International	$677.56 million	8.84	$59.01 million	$0.97	79.12

Kiniksa Pharmaceuticals International has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Summary

Kiniksa Pharmaceuticals International beats Revolution Medicines on 9 of the 15 factors compared between the two stocks.

About Revolution Medicines

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company’s RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.